Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WBD156
- Development stage
- Unknown
- Lead developer
- Wayne Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
WBD156 is an investigational oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed by Wayne Biosciences (韦恩生物) for the treatment of obesity and overweight. As a small molecule GLP-1RA, it is designed to provide a more convenient oral dosing alternative to injectable peptide-based GLP-1 therapies. The drug is currently in Phase I clinical development, where it is being evaluated for safety, tolerability, pharmacokinetics, and preliminary efficacy in healthy and overweight or obese volunteers. The program is part of Wayne Biosciences' pipeline focused on metabolic and endocrine disorders.
02
Targets
Beyond the preview
Go deeper on WBD156.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WBD156.